Takeda, Asia's largest pharmaceutical company, sells plant in Russia
After the invasion began, Takeda suspended new clinical trials in Russia and halted all investments
The Japanese pharmaceutical manufacturer Takeda, one of the 15 largest pharmaceutical companies in the world, intends to sell its plant in Yaroslavl, Russia.
Source. Kommersant writes about this with reference to two sources in the pharmaceutical market and one of the officials in the region.
Several companies have already expressed interest in buying the plant, but there have been no concrete offers. Takeda's Russian office declined to comment, calling the information "rumors."
A source in the pharmaceutical market said that the sale of the plant does not mean that the company will completely shut down its business in Russia.
After the start of Russia's invasion of Ukraine, Takeda suspended new clinical trials in Russia and stopped all investments in Russian projects, but decided to stay in the market.
Over the past ten years, the Japanese pharmaceutical company has invested 117.43 million euros in the plant in Yaroslavl. The company produces the most popular drug Nilaro. Last year, the volume of supplies of this drug under public procurement amounted to $55 million, twice as much as in 2019-2021.
Takeda is the largest pharmaceutical company in Asia. In the CIS market, it produces Actovegin, Cardiomagnyl, Calcium-D3 Nicomed, Ceraxon, Ximelin, Xefocam, and others. The revenue of Takeda's Russian business in 2021 amounted to 21.9 billion rubles.
Background. As a reminder, French Leroy Merlin is leaving Russia, why it is important – in the Mind article "Leroy Merlin is finally leaving Russia. Why it happened only now and what made the chain give up.
If you have read this article to the end, we hope that means it was useful for you.
We work to ensure that our journalistic and analytical work is of high quality, and we strive to perform it as competently as possible. This also requires financial independence. Support us for only UAH 196 per month.
Become a Mind subscriber for just USD 5 per month and support the development of independent business journalism!
You can unsubscribe at any time in your LIQPAY account or by sending us an email: [email protected]
